Poitiers

• A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic … Recruiting
  2024-512423-36-00 5 2024-11-20 Leiomyosarcoma (non-uterine)
• NEOADJUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MU … Recruiting
  2024-519113-59-00 4 2024-11-20 Hepatocellular carcinoma
• CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al … Recruiting
  2024-517004-11-00 5 2024-10-22 Chronic pulmonary aspergillosis
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4 … Recruiting
  2022-502825-17-00 4 2024-10-07 Melanoma
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 4 2024-10-02 Locally advanced or metastatic urothelial cancer
• CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) P … Recruiting
  2024-516328-32-00 4 2024-09-16 CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re … Recruiting
  2023-504918-29-00 5 2024-08-22 Hormone receptor positive breast cancer
• A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting
  2023-507555-29-00 9 2024-08-16 LA/mGC/GEJC (locally advanced unresectable or metastatic gastric cance
• A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relap … Recruiting
  2023-507901-32-00 3 2024-06-28 Relapsed or Refractory Multiple Myeloma (R/R MM)
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• Long–term Analysis of DImethyl fumarate, to slow the Growth of Areas of Geographic Atrophy Recruiting
  2024-510741-33-00 4 2024-06-27 Macular degeneration
• A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma Recruiting
  2023-505775-70-00 4 2024-04-08 High risk smoldering multiple myeloma
• Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international … Recruiting
  2023-508153-12-00 5 2024-03-26 Hospital-acquired pneumonia
• Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting
  2023-503523-25-00 4 2024-02-29 Non-small cell lung cancer
• ENGIC 02 - PRODIGE 86-FOLFIRINOX SBA- Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanc … Recruiting
  2023-505486-92-00 4 2024-02-09 Small bowel adenocarcinoma
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors Recruiting
  2022-502654-14-00 4 2023-09-11 Endometrial cancer
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting
  2023-510275-64-00 9 2023-05-31 Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or ot
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting
  2022-501893-21-00 4 2022-05-03 Acute myocardial infarction
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate

Showing 73–96 of 615 trials